QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.00 (-1.68%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.00 (-1.68%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.00 (-1.68%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.00 (-1.68%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
NYSE:NBY

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

$0.08
-0.01 (-9.85%)
(As of 04:28 PM ET)
Today's Range
$0.08
$0.09
50-Day Range
$0.09
$0.17
52-Week Range
$0.08
$1.95
Volume
1.64 million shs
Average Volume
3.35 million shs
Market Capitalization
$2.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NBY stock logo

About NovaBay Pharmaceuticals Stock (NYSE:NBY)

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NBY Stock Price History

NBY Stock News Headlines

See More Headlines
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
4/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
24
Year Founded
N/A

Profitability

Net Income
$-9,640,000.00
Pretax Margin
-65.46%

Debt

Sales & Book Value

Annual Sales
$14.73 million
Book Value
$0.12 per share

Miscellaneous

Free Float
35,592,000
Market Cap
$3.11 million
Optionable
Not Optionable
Beta
1.97
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Justin M. Hall Esq. (Age 46)
    President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director
    Comp: $364.15k
  • Mr. Tommy Law (Age 39)
    Controller, Interim CFO & Treasurer
    Comp: $155.48k

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed in 2024?

NovaBay Pharmaceuticals' stock was trading at $0.2040 on January 1st, 2024. Since then, NBY stock has decreased by 57.4% and is now trading at $0.0869.
View the best growth stocks for 2024 here
.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) issued its earnings results on Tuesday, March, 26th. The company reported ($0.95) EPS for the quarter. The company earned $3.73 million during the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 150.14% and a negative net margin of 65.46%.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include OpGen (OPGN) and Abbott Laboratories (ABT).

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NBY) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners